Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma by Miaoyan Wei, Rujiao Liu, Yunyun Xu, Xiaobing Chen, Chao Liu, Xueli Bai, Xiaochen Zhang, Shuiping Gao, Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang, Jian Zhang, Si Shi, Jin Xu, Xianjun Yu

Get full text

Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma by Miaoyan Wei, Rujiao Liu, Yunyun Xu, Xiaobing Chen, Chao Liu, Xueli Bai, Xiaochen Zhang, Shuiping Gao, Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang, Jian Zhang, Si Shi, Jin Xu, Xianjun Yu

Get full text

Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients... by Hongkai Wang, Shusuan Jiang, Hong Luo, Fangjian Zhou, Dalin He, Lulin Ma, Hongqian Guo, Chaozhao Liang, Tie Chong, Jun Jiang, Zhiwen Chen, Yong Wang, Qing Zou, Ye Tian, Jun Xiao, Jian Huang, Jinchao Chen, Qiang Dong, Xiaoping Zhang, Hanzhong Li, Xinfeng Yang, Jianpo Lian, Wenliang Wang, Dingwei Ye

Get full text